Core Viewpoint - The stock of Baiaosaitu-B (02315) has increased by over 5%, reaching 36.08 HKD, following its inclusion in the Hong Kong Stock Connect list, which opens access to mainland investors starting December 24, 2025 [1] Group 1: Company Developments - Baiaosaitu-B has been officially added to the Hong Kong Stock Connect list, marking a significant milestone in establishing its "A+H" dual capital market platform [1] - The stock's recent performance reflects the company's growth potential, with a reported trading volume of 27.5841 million HKD [1] Group 2: Analyst Insights - Huafu Securities has issued a report indicating that the company's antibody authorization is beginning to yield results, driving a surge in performance [1] - The report highlights the company's high growth potential and strong barriers to entry, with a solid foundation in preclinical animal and pharmacological evaluations [1] - The antibody development business is entering a phase of performance realization, complemented by a promising pipeline of potential new drugs, leading to an initial "buy" rating [1]
港股异动 再涨超5% 公司近期正式进入港股通名单 机构称千鼠万抗开始兑现